{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:45:59Z","timestamp":1791639959377,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04271-4","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:01:19Z","timestamp":1751558479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dilemma of missing specific disease codes: an approach to assess the incidence and prevalence of a rare nephrology disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Matthias","family":"Roll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadeus","family":"Gladbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Selinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Himmelhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timotheus","family":"Stremel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Theil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"4271_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data analyses in Germany-A systematic review. Health Policy (Amsterdam, Netherlands). 2016;120(2):213\u201326.","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"4271_CR2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) im Auftrag des Bundesministeriums f\u00fcr Gesundheit (BMG) unter Beteiligung der Arbeitsgruppe ICD des Kuratoriums f\u00fcr Fragen der Klassifikation im Gesundheitswesen (KKG). ICD-10-GM Version 2024, Systematisches Verzeichnis, Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. (Stand: 15. September 2023); [Available from: https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Services\/Downloads\/_node.html#anker-icd-10-gm-downloads. Accessed 22.01.2025."},{"issue":"2","key":"4271_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/jheor.2021.26129","volume":"8","author":"CS Kwon","year":"2021","unstructured":"Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res. 2021;8(2):36\u201345.","journal-title":"J Health Econ Outcomes Res"},{"issue":"25","key":"4271_CR4","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"10433","key":"4271_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","volume":"403","author":"K Wong","year":"2024","unstructured":"Wong K, Pitcher D, Braddon F, et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK national registry of rare kidney diseases (RaDaR) cohort. Lancet (London, England). 2024;403(10433):1279\u201389.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"4271_CR6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/ki.2015.252","volume":"88","author":"R Magistroni","year":"2015","unstructured":"Magistroni R, D\u2019Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974\u201389.","journal-title":"Kidney Int"},{"issue":"6","key":"4271_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in iga nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4271_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"4271_CR9","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/ndt\/gfad082","volume":"38","author":"CJ Willey","year":"2023","unstructured":"Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023;38(10):2340\u201349.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"4271_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s11255-011-9955-4","volume":"43","author":"N Braun","year":"2011","unstructured":"Braun N, Schweisfurth A, Loh\u00f6fener C, et al. Epidemiology of glomerulonephritis in Northern Germany. Int Urol Nephrol. 2011;43(4):1117\u201326.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"4271_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/ckj\/sfz023","volume":"12","author":"CM Zink","year":"2019","unstructured":"Zink CM, Ernst S, Riehl J, et al. Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013. Clin Kidney J. 2019;12(6):795\u2013800.","journal-title":"Clin Kidney J"},{"key":"4271_CR12","unstructured":"Statistisches Bundesamt DESTATIS. Bev\u00f6lkerungsstand. Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht (Quartalszahlen). 2023 Available from https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html#616584. Accessed 22.01.2025."},{"key":"4271_CR13","unstructured":"Bundesministerium f\u00fcr Gesundheit. Gesetzliche krankenversicherung. mitglieder, mitversicherte angeh\u00f6rige und krankenstand. Jahresdurchschnitt 2022 (Ergebnisse der GKV-Statistik KM 1\/13) 2023 [Available from: https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_JD_2022_1_bf.pdf. Accessed 22.01.2025."},{"key":"4271_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","volume":"206","author":"M Ludwig","year":"2022","unstructured":"Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health. 2022;206:57\u201362.","journal-title":"Public Health"},{"key":"4271_CR15","unstructured":"Dunnikan K Confidence interval calculation for binomial proportions 2008 [Available from: https:\/\/www.mwsug.org\/proceedings\/2008\/pharma\/MWSUG-2008-P08.pdf. Accessed 22.01.2025."},{"issue":"1","key":"4271_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12882-024-03555-5","volume":"25","author":"O Zaidi","year":"2024","unstructured":"Zaidi O, Du F, Tang Z, Bhattacharjee S, Pareja K. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries. BMC Nephrol. 2024;25(1):136.","journal-title":"BMC Nephrol"},{"issue":"Supplement_2","key":"4271_CR17","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","volume":"16","author":"M Lee","year":"2023","unstructured":"Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023;16(Supplement_2):ii1\u2013ii8.","journal-title":"Clin Kidney J"},{"issue":"8","key":"4271_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.34067\/KID.0002972021","volume":"2","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Monteiro RC, Coppo R, Suzuki H. The phenotypic difference of iga nephropathy and its race\/gender-dependent molecular mechanisms. Kidney 360. 2021;2(8):1339\u201348.","journal-title":"Kidney360"},{"issue":"9","key":"4271_CR19","doi-asserted-by":"publisher","first-page":"100693","DOI":"10.1016\/j.xkme.2023.100693","volume":"5","author":"EV Lerma","year":"2023","unstructured":"Lerma EV, Bensink ME, Thakker KM, et al. Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with iga nephropathy in the united states: a retrospective analysis. Kidney Med. 2023;5(9):100693.","journal-title":"Kidney Med"},{"key":"4271_CR20","unstructured":"Regulation OMP. Regulation (EC) No 141\/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Off J. 2000;18:15."},{"key":"4271_CR21","doi-asserted-by":"publisher","first-page":"1574239","DOI":"10.3389\/fneph.2025.1574239","volume":"5","author":"G Pesce","year":"2025","unstructured":"Pesce G, Patel M, Gusto G, Kadambi A, Chandak A, Madison T. Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort. Front Nephrol. 2025;5:1574239.","journal-title":"Front Nephrol"},{"key":"4271_CR22","doi-asserted-by":"crossref","unstructured":"Azegami T, Kaneko H, Okada A, et al. Association between rheumatoid arthritis and the incidence of iga nephropathy. Am J Nephrol. 2025;1\u201317.","DOI":"10.1159\/000546196"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04271-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04271-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:01:21Z","timestamp":1751558481000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04271-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04271-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claims data from the participating SHIs are joined in a specialized trust centre, anonymized, and transferred to InGef before the data are made available for research. The analysis of claims data from the SHI is fully compliant with German federal law and in accordance with the \u201cGPS \u2013 Good Practice in Secondary Data Analysis\u201d (Guideline 1: Ethics), the approval of an ethics committee and informed consent of the patients were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Matthias Roll, Amadeus Gladbach, Isabella Selinger and Thomas Hardt are full-time employees of CSL Vifor. Helena Himmelhaus, Christian Jacob, Timotheus Stremel and Julia Theil are a full-time employees of PharmaLex GmbH, part of Cencora Inc., acting as contractors of CSL Vifor for the execution of this study. J\u00fcrgen Floege has received consultancy and\/or lecture fees from AstraZeneca, Bayer, Boehringer, CSL Vifor, HiBio, Novartis, Roche, Stadapharm, Travere, Vera Therapeutics and serves on data safety monitoring boards of NovoNordisk and Visterra.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}